구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | gene expression analysis (gene expression analysis) ECOG-ACRIN Cancer Research Group·Breast Cancer 157 trials |
|---|---|
Overview Program | gene expression analysis |
Overview Company | ECOG-ACRIN Cancer Research Group |
Overview Modality | ANTIBODY |
Overview Target | Breast Cancer |
Overview Indication | Head and Neck Cancer |
Overview Phase | PHASE_2 |
Overview Status | DISCONTINUED |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
MoA Mechanism | , represents a significant advance in phytomedicine-based approaches to obesity treatment |
MoA Biomarker | biomarkers in Crohn's disease |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | PK |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Glycoconjugate strategy for GLUT-driven curcumin delivery and anticancer activity in breast cancer cells.. Selective targeting of cancer cells is a critical strategy in anticancer therapy, and the overexpression of glucose transporters (GLUTs) in malignant cells provides an attractive avenue for achieving this selectivity. In this study, we report the synthesis and biological evaluation of glycoco… |
Clinical Safety signal | Glycoconjugate strategy for GLUT-driven curcumin delivery and anticancer activity in breast cancer cells.. Selective targeting of cancer cells is a critical strategy in anticancer therapy, and the overexpression of glucose transporters (GLUTs) in malignant cells provides an attractive avenue for achieving this selectivity. In this study, we report the synthesis and biological evaluation of glycoco… |
Clinical Selected reported efficacy | ORR 5% |
Clinical Reported ORR | 5% |
Clinical Result source | ClinicalTrials.gov NCT00540722 |
Clinical Program phase | PHASE_2 |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | NCT00540722 |
Preclinical Animal (cat.) | In vitro |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | gene expression analysis (gene expression analysis) ECOG-ACRIN Cancer Research Group·Breast Cancer 157 trials |
|---|---|
Overview Program | gene expression analysis |
Overview Company | ECOG-ACRIN Cancer Research Group |
Overview Modality | ANTIBODY |
Overview Target | Breast Cancer |
Overview Indication | Head and Neck Cancer |
Overview Phase | PHASE_2 |
Overview Status | DISCONTINUED |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
MoA Mechanism | , represents a significant advance in phytomedicine-based approaches to obesity treatment |
MoA Biomarker | biomarkers in Crohn's disease |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | PK |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Glycoconjugate strategy for GLUT-driven curcumin delivery and anticancer activity in breast cancer cells.. Selective targeting of cancer cells is a critical strategy in anticancer therapy, and the overexpression of glucose transporters (GLUTs) in malignant cells provides an attractive avenue for achieving this selectivity. In this study, we report the synthesis and biological evaluation of glycoco… |
Clinical Safety signal | Glycoconjugate strategy for GLUT-driven curcumin delivery and anticancer activity in breast cancer cells.. Selective targeting of cancer cells is a critical strategy in anticancer therapy, and the overexpression of glucose transporters (GLUTs) in malignant cells provides an attractive avenue for achieving this selectivity. In this study, we report the synthesis and biological evaluation of glycoco… |
Clinical Selected reported efficacy | ORR 5% |
Clinical Reported ORR | 5% |
Clinical Result source | ClinicalTrials.gov NCT00540722 |
Clinical Program phase | PHASE_2 |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | NCT00540722 |
Preclinical Animal (cat.) | In vitro |
추천 비교
추천 비교